Cargando…

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades

We have used a non-myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation for the past 20 years. During that period, changes in clinical practice have been aimed at reducing morbidity and mortality from infections, organ toxicity, and graft-versus-host disease. We hypot...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooper, Jason P., Storer, Barry E., Granot, Noa, Gyurkocza, Boglarka, Sorror, Mohamed L., Chauncey, Thomas R., Shizuru, Judith, Franke, Georg-Nikolaus, Maris, Michael B., Boyer, Michael, Bruno, Benedetto, Sahebi, Firoozeh, Langston, Amelia A., Hari, Parameswaran, Agura, Edward D., Petersen, Søren Lykke, Maziarz, Richard T., Bethge, Wolfgang, Asch, Julie, Gutman, Jonathan A., Olesen, Gitte, Yeager, Andrew M., Hübel, Kai, Hogan, William J., Maloney, David G., Mielcarek, Marco, Martin, Paul J., Flowers, Mary E. D., Georges, George E., Woolfrey, Ann E., Deeg, H. Joachim, Scott, Bart L., McDonald, George B., Storb, Rainer, Sandmaier, Brenda M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168504/
https://www.ncbi.nlm.nih.gov/pubmed/32499241
http://dx.doi.org/10.3324/haematol.2020.248187
_version_ 1783701891016818688
author Cooper, Jason P.
Storer, Barry E.
Granot, Noa
Gyurkocza, Boglarka
Sorror, Mohamed L.
Chauncey, Thomas R.
Shizuru, Judith
Franke, Georg-Nikolaus
Maris, Michael B.
Boyer, Michael
Bruno, Benedetto
Sahebi, Firoozeh
Langston, Amelia A.
Hari, Parameswaran
Agura, Edward D.
Petersen, Søren Lykke
Maziarz, Richard T.
Bethge, Wolfgang
Asch, Julie
Gutman, Jonathan A.
Olesen, Gitte
Yeager, Andrew M.
Hübel, Kai
Hogan, William J.
Maloney, David G.
Mielcarek, Marco
Martin, Paul J.
Flowers, Mary E. D.
Georges, George E.
Woolfrey, Ann E.
Deeg, H. Joachim
Scott, Bart L.
McDonald, George B.
Storb, Rainer
Sandmaier, Brenda M.
author_facet Cooper, Jason P.
Storer, Barry E.
Granot, Noa
Gyurkocza, Boglarka
Sorror, Mohamed L.
Chauncey, Thomas R.
Shizuru, Judith
Franke, Georg-Nikolaus
Maris, Michael B.
Boyer, Michael
Bruno, Benedetto
Sahebi, Firoozeh
Langston, Amelia A.
Hari, Parameswaran
Agura, Edward D.
Petersen, Søren Lykke
Maziarz, Richard T.
Bethge, Wolfgang
Asch, Julie
Gutman, Jonathan A.
Olesen, Gitte
Yeager, Andrew M.
Hübel, Kai
Hogan, William J.
Maloney, David G.
Mielcarek, Marco
Martin, Paul J.
Flowers, Mary E. D.
Georges, George E.
Woolfrey, Ann E.
Deeg, H. Joachim
Scott, Bart L.
McDonald, George B.
Storb, Rainer
Sandmaier, Brenda M.
author_sort Cooper, Jason P.
collection PubMed
description We have used a non-myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation for the past 20 years. During that period, changes in clinical practice have been aimed at reducing morbidity and mortality from infections, organ toxicity, and graft-versus-host disease. We hypothesized that improvements in clinical practice led to better transplantation outcomes over time. From 1997–2017, 1,720 patients with hematologic malignancies received low-dose total body irradiation ± fludarabine or clofarabine before transplantation from HLAmatched sibling or unrelated donors, followed by mycophenolate mofetil and a calcineurin inhibitor ± sirolimus. We compared outcomes in three cohorts by year of transplantation: 1997–2003 (n=562), 2004–2009 (n =594), and 2010–2017 (n=564). The proportion of patients ≥60 years old increased from 27% in 1997–2003 to 56% in 2010–2017, and with scores from the Hematopoietic Cell Transplantation Comorbidity Index of ≥3 increased from 25% in 1997–2003 to 45% in 2010–2017. Use of unrelated donors increased from 34% in 1997–2003 to 65% in 2010–2017. When outcomes from 2004–2009 and 2010–2017 were compared to 1997–2003, improvements were noted in overall survival (P=0.0001 for 2004–2009 and P≤0.0001 for 2010–2017), progression-free survival (P=0.002 for 2004–2009 and P<0.0001 for 2010–2017), non-relapse mortality (P<0.0001 for 2004– 2009 and P<0.0001 for 2010–2017), and in rates of grades 2–4 acute and chronic graft-versus-host disease. For patients with hematologic malignancies who underwent transplantation with non-myeloablative conditioning, outcomes have improved during the past two decades. Trials reported are registered under clinicaltrials gov. Identifiers: NCT00003145, NCT00003196, 005803, NCT00006251, NCT00014235, NCT00027820, NCT00031655, NCT00036738, NCT00045435, NCT00052546, NCT00060424, NCT00075478, NCT00078858, NCT00089011, NCT00104858, NCT00105001, NCT00110058, NCT00397813, NCT00793572, NCT01231412, NCT01252667, NCT01527045.
format Online
Article
Text
id pubmed-8168504
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Fondazione Ferrata Storti
record_format MEDLINE/PubMed
spelling pubmed-81685042021-06-11 Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades Cooper, Jason P. Storer, Barry E. Granot, Noa Gyurkocza, Boglarka Sorror, Mohamed L. Chauncey, Thomas R. Shizuru, Judith Franke, Georg-Nikolaus Maris, Michael B. Boyer, Michael Bruno, Benedetto Sahebi, Firoozeh Langston, Amelia A. Hari, Parameswaran Agura, Edward D. Petersen, Søren Lykke Maziarz, Richard T. Bethge, Wolfgang Asch, Julie Gutman, Jonathan A. Olesen, Gitte Yeager, Andrew M. Hübel, Kai Hogan, William J. Maloney, David G. Mielcarek, Marco Martin, Paul J. Flowers, Mary E. D. Georges, George E. Woolfrey, Ann E. Deeg, H. Joachim Scott, Bart L. McDonald, George B. Storb, Rainer Sandmaier, Brenda M. Haematologica Article We have used a non-myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation for the past 20 years. During that period, changes in clinical practice have been aimed at reducing morbidity and mortality from infections, organ toxicity, and graft-versus-host disease. We hypothesized that improvements in clinical practice led to better transplantation outcomes over time. From 1997–2017, 1,720 patients with hematologic malignancies received low-dose total body irradiation ± fludarabine or clofarabine before transplantation from HLAmatched sibling or unrelated donors, followed by mycophenolate mofetil and a calcineurin inhibitor ± sirolimus. We compared outcomes in three cohorts by year of transplantation: 1997–2003 (n=562), 2004–2009 (n =594), and 2010–2017 (n=564). The proportion of patients ≥60 years old increased from 27% in 1997–2003 to 56% in 2010–2017, and with scores from the Hematopoietic Cell Transplantation Comorbidity Index of ≥3 increased from 25% in 1997–2003 to 45% in 2010–2017. Use of unrelated donors increased from 34% in 1997–2003 to 65% in 2010–2017. When outcomes from 2004–2009 and 2010–2017 were compared to 1997–2003, improvements were noted in overall survival (P=0.0001 for 2004–2009 and P≤0.0001 for 2010–2017), progression-free survival (P=0.002 for 2004–2009 and P<0.0001 for 2010–2017), non-relapse mortality (P<0.0001 for 2004– 2009 and P<0.0001 for 2010–2017), and in rates of grades 2–4 acute and chronic graft-versus-host disease. For patients with hematologic malignancies who underwent transplantation with non-myeloablative conditioning, outcomes have improved during the past two decades. Trials reported are registered under clinicaltrials gov. Identifiers: NCT00003145, NCT00003196, 005803, NCT00006251, NCT00014235, NCT00027820, NCT00031655, NCT00036738, NCT00045435, NCT00052546, NCT00060424, NCT00075478, NCT00078858, NCT00089011, NCT00104858, NCT00105001, NCT00110058, NCT00397813, NCT00793572, NCT01231412, NCT01252667, NCT01527045. Fondazione Ferrata Storti 2020-06-04 /pmc/articles/PMC8168504/ /pubmed/32499241 http://dx.doi.org/10.3324/haematol.2020.248187 Text en Copyright© 2021 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Article
Cooper, Jason P.
Storer, Barry E.
Granot, Noa
Gyurkocza, Boglarka
Sorror, Mohamed L.
Chauncey, Thomas R.
Shizuru, Judith
Franke, Georg-Nikolaus
Maris, Michael B.
Boyer, Michael
Bruno, Benedetto
Sahebi, Firoozeh
Langston, Amelia A.
Hari, Parameswaran
Agura, Edward D.
Petersen, Søren Lykke
Maziarz, Richard T.
Bethge, Wolfgang
Asch, Julie
Gutman, Jonathan A.
Olesen, Gitte
Yeager, Andrew M.
Hübel, Kai
Hogan, William J.
Maloney, David G.
Mielcarek, Marco
Martin, Paul J.
Flowers, Mary E. D.
Georges, George E.
Woolfrey, Ann E.
Deeg, H. Joachim
Scott, Bart L.
McDonald, George B.
Storb, Rainer
Sandmaier, Brenda M.
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades
title Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades
title_full Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades
title_fullStr Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades
title_full_unstemmed Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades
title_short Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades
title_sort allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168504/
https://www.ncbi.nlm.nih.gov/pubmed/32499241
http://dx.doi.org/10.3324/haematol.2020.248187
work_keys_str_mv AT cooperjasonp allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT storerbarrye allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT granotnoa allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT gyurkoczaboglarka allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT sorrormohamedl allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT chaunceythomasr allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT shizurujudith allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT frankegeorgnikolaus allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT marismichaelb allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT boyermichael allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT brunobenedetto allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT sahebifiroozeh allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT langstonameliaa allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT hariparameswaran allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT aguraedwardd allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT petersensørenlykke allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT maziarzrichardt allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT bethgewolfgang allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT aschjulie allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT gutmanjonathana allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT olesengitte allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT yeagerandrewm allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT hubelkai allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT hoganwilliamj allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT maloneydavidg allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT mielcarekmarco allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT martinpaulj allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT flowersmaryed allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT georgesgeorgee allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT woolfreyanne allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT deeghjoachim allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT scottbartl allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT mcdonaldgeorgeb allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT storbrainer allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades
AT sandmaierbrendam allogeneichematopoieticcelltransplantationwithnonmyeloablativeconditioningforpatientswithhematologicmalignanciesimprovedoutcomesovertwodecades